Association of Anti–Factor Xa–Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Surgery"
DOI: 10.1001/jamasurg.2017.3787
Abstract: Importance The efficacy of anti–factor Xa (anti-Xa)–guided dosing of thromboprophylaxis after trauma remains controversial. Objective To assess whether dosing of enoxaparin sodium based on peak anti-Xa levels is associated with the venous thromboembolism (VTE) rate… read more here.
Keywords: vte; group; trauma; guided dosing ... See more keywords
Anticoagulant Heparin Mimetics via RAFT Polymerization.
Sign Up to like & getrecommendations! Published in 2019 at "Biomacromolecules"
DOI: 10.1021/acs.biomac.9b01688
Abstract: Heparin, a sulfated polysaccharide derived from animal sources, is the most commonly used parenteral anticoagulant drug, but suffers from significant safety and supply issues. Herein, we describe the preparation of heparin mimetic homo- and copolymers… read more here.
Keywords: anticoagulant heparin; raft polymerization; anti factor; raft ... See more keywords
525: ANTI-FACTOR XA LEVELS IN PICU PATIENTS ON ENOXAPARIN FOR VENOTHROMBOEMBOLISM PROPHYLAXIS
Sign Up to like & getrecommendations! Published in 2019 at "Critical Care Medicine"
DOI: 10.1097/01.ccm.0000551277.86961.15
Abstract: Learning Objectives: Pediatric Intensive Care Unit (PICU) patients are at higher risk for venothromboembolism (VTE) than other hospitalized patients for a variety of reasons. Options for VTE prophylaxis are mechanical or chemical. An often chosen… read more here.
Keywords: patients enoxaparin; venothromboembolism; vte prophylaxis; picu patients ... See more keywords
Anti‐factor VIII antibodies in brothers with haemophilia A share similar characteristics
Sign Up to like & getrecommendations! Published in 2017 at "Haemophilia"
DOI: 10.1111/hae.13105
Abstract: The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is currently the most serious complication for patients with haemophilia A undergoing FVIII replacement therapy. Several genetic factors have been acknowledged as risk factors… read more here.
Keywords: antibodies brothers; factor viii; viii antibodies; factor ... See more keywords
Methods for anti‐factor VIII antibody levels in haemophilia A patients – validation of a multiplex immunoassay and comparability with assays measuring non‐neutralising and neutralising antibodies (inhibitors)
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14669
Abstract: The development of neutralising (inhibitors) and non‐neutralising antibodies (NNAs) is a complication to factor replacement therapy in haemophilia. The diagnostic methods available lack standardisation, have high inter‐laboratory variation, and false‐negative as well as false‐positive results… read more here.
Keywords: anti factor; methods anti; factor viii; neutralising antibodies ... See more keywords
Identification of non‐neutralizing anti‐factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14711
Abstract: Autoimmune factor X (FX or F10) deficiency (AiF10D) is an extremely rare acquired haemorrhagic disorder characterized by a severe reduction in FX activity due to autoantibodies against FX. read more here.
Keywords: non neutralizing; anti factor; identification non; neutralizing anti ... See more keywords
Anti-factor H antibody and its role in atypical hemolytic uremic syndrome
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.931210
Abstract: Atypical hemolytic uremic syndrome (aHUS) an important form of a thrombotic microangiopathy (TMA) that can frequently lead to acute kidney injury (AKI). An important subset of aHUS is the anti-factor H associated aHUS. This variant… read more here.
Keywords: anti factor; associated ahus; atypical hemolytic; factor ... See more keywords
Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol.
Sign Up to like & getrecommendations! Published in 2020 at "AACN advanced critical care"
DOI: 10.4037/aacnacc2020132
Abstract: BACKGROUND The VA Northeast Ohio Healthcare System introduced a new nurse-driven anti-factor Xa (anti-Xa) protocol for monitoring unfractionated heparin to replace the previous activated partial thromboplastin time protocol. OBJECTIVE To design, implement, and evaluate the… read more here.
Keywords: heparin; time; monitoring protocol; protocol ... See more keywords
Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Thoracic Medicine"
DOI: 10.4103/atm.atm_31_17
Abstract: Background: Venous thromboembolism (VTE) can be encountered by 60% of hospitalized patients. Anticoagulants have been recommended to reduce the risk of VTE in patients with risk factors. However, no specific dosing recommendations for obese patients… read more here.
Keywords: morbidly obese; venous thromboembolism; weight based; anti factor ... See more keywords
No effect of norepinephrine dose on anti-Xa activity in critically ill patients .
Sign Up to like & getrecommendations! Published in 2020 at "International journal of clinical pharmacology and therapeutics"
DOI: 10.5414/cp203640
Abstract: OBJECTIVE Low-molecular-weight heparins are frequently used to prevent venous thromboembolism. Vasopressor therapy may be associated with inadequate anti-factor Xa activity, thereby increasing the risk of venous thromboembolism. We aimed to assess the association between anti-factor… read more here.
Keywords: activity; norepinephrine dose; factor; dose anti ... See more keywords